Daniella Mehalik
Finanzdirektor/CFO bei PSYCHEMEDICS CORPORATION
Aktive Positionen von Daniella Mehalik
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| PSYCHEMEDICS CORPORATION | Finanzdirektor/CFO | 27.11.2023 | - |
| Investor Relations Kontakt | - | - | |
| Treasurer | 27.11.2023 | - |
Karriereverlauf von Daniella Mehalik
Ehemalige bekannte Positionen von Daniella Mehalik
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| NEUBASE THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 01.01.2021 | 01.01.2023 |
| DxTx Medical, Inc. | Comptroller/Controller/Auditor | 01.01.2019 | 01.01.2021 |
Ausbildung von Daniella Mehalik
| Carlow University Of | Graduate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
Operativ
| Comptroller/Controller/Auditor | 2 |
| Director of Finance/CFO | 1 |
| Investor Relations Contact | 1 |
Sektoral
| Health Services | 2 |
| Consumer Services | 2 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| PSYCHEMEDICS CORPORATION | Health Services |
| Private Unternehmen | 2 |
|---|---|
NeuBase Therapeutics, Inc.
 NeuBase Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm’s therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. The company was founded by Dietrich A. Stephan on August 4, 2009 and is headquartered in Pittsburgh, PA. | Health Technology |
| DxTx Medical, Inc. |
- Börse
- Insiders
- Daniella Mehalik
- Erfahrung
